Why the study?
Hypertension affects >80% of dialysis patients, but evidence guiding its management remains limited and reliable, objective methods to assess extracellular volume are lacking.
This review highlights the critical gaps in evidence for treating hypertension in ESKD patients on dialysis and underscores the importance of objective volume assessment and non-dialysis blood pressure monitoring.
Hypertension is a highly prevalent and modifiable risk factor, affecting >80% of patients undergoing dialysis. Its pathophysiology is complex and differs from that of the general population, driven by factors such as volume overload, arterial stiffness, overactivation of the sympathetic and renin-angiotensin-aldosterone systems, and endothelial dysfunction. Achieving optimal blood pressure and volume control is central to dialysis care, with significant implications for cardiovascular outcomes and patient quality of life. Despite its importance, evidence guiding hypertension management in this population remains limited. Furthermore, reliable, objective methods to assess extracellular volume are lacking. This review examines current approaches to the assessment and management of hypertension in maintenance hemodialysis, summarizing existing evidence, clinical guidelines, and ongoing challenges in blood pressure and volume control.
No takes yet. Share an insight, caveat, or question.
Mayeda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: